Neuronetics Q4 Earnings Call Highlights
View original at finance.yahoo.comNeuronetics Q4 Earnings Call Highlights Neuronetics logo Key Points Board appointed Dan Reuvers as CEO effective March 23, as Neuronetics transitions leadership while continuing its strategy to operate a vertically integrated mental-health company combining NeuroStar technology and Greenbrook clinics…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
Fourth-quarter total revenue was $41.8 million, up 86% year-over-year, primarily due to the inclusion of Greenbrook operations. On an adjusted pro forma basis, revenue increased 23% versus the prior year
60% confidenceThe fourth-quarter gross margin was the company's highest quarterly margin of the year, citing clinic efficiency efforts and favorable product mix
60% confidenceThe debt paydown would reduce annual interest expense by close to $600,000
60% confidenceThe Greenbrook network is positioned to offer REMS-compliant therapies and expects only limited incremental investment to support COMP360 if approved, given alignment with existing Spravato operations
60% confidenceFull-year 2026 operating cash flow is expected to be negative $13 million to negative $17 million, with the highest cash burn in the first quarter and improvement beginning in the second quarter, with positive operating cash flow in the second half
60% confidenceThe company's strategy following the Greenbrook acquisition was to build a vertically integrated mental health company combining technology, clinical infrastructure, and scale to expand patient access to treatment
60% confidenceThe debt paydown would reduce annual interest expense by close to $600,000
60% confidenceThe debt paydown would reduce annual interest expense by close to $600,000
60% confidenceThe company shipped 49 systems in the quarter, with average selling price above its target for a fourth consecutive quarter
60% confidenceThe company shipped 49 systems in the quarter with average selling price above its target for a fourth consecutive quarter
60% confidenceThe Greenbrook network is positioned to offer REMS-compliant therapies and expects only limited incremental investment to support COMP360 if approved, given alignment with existing Spravato operations
60% confidenceCompass has about seven strategic collaborations for commercial readiness and Greenbrook is one of them
60% confidenceCOMP360 would be administered in supervised doses within a clinic setting, without a daily or recurring protocol, and would be administered under a REMS protocol similar to Spravato
60% confidenceThe field team held more than 400 educational meetings, resulting in more than 210 new referral sites by year-end
60% confidenceCompass Pathways has completed two phase 3 studies showing highly statistically significant and clinically meaningful results, including durable improvement through at least 26 weeks after one or two doses
60% confidenceTotal cash was $34.1 million at Dec. 31, 2025, including $28.1 million of cash and cash equivalents and $6.0 million of restricted cash, compared with $19.5 million at year-end 2024
60% confidenceFull-year clinic revenue grew 28% on an adjusted pro forma basis, supported by increased field engagement and a growing network of referring providers
60% confidenceThe company's strategy following the Greenbrook acquisition was to build a vertically integrated mental health company combining technology, clinical infrastructure, and scale to expand patient access to treatment
60% confidenceFor 2026, total revenue guidance of $160 million to $166 million implies greater than 9% growth versus 2025, with clinic business expected to grow in the double digits to mid-teens and NeuroStar business expected to grow in the low to mid-single digits
60% confidenceSpravato rollout is nearly complete with 84 clinics providing the treatment
60% confidenceThe Greenbrook network is positioned to offer REMS-compliant therapies and expects only limited incremental investment to support COMP360 if approved, given alignment with existing Spravato operations
60% confidenceThe Spravato rollout is nearly complete, with 84 clinics providing the treatment
60% confidenceThe company has optimized billing practices based on the economics of buy and bill versus administer and observe, and is deploying billing models in a state-, payer-, and clinic-specific manner
60% confidenceThe clinic business is expected to grow in the double digits to mid-teens, while the NeuroStar business is expected to grow in the low to mid-single digits
60% confidenceThe company's strategy following the Greenbrook acquisition was to build a vertically integrated mental health company combining technology, clinical infrastructure, and scale to expand patient access to treatment
60% confidenceThe company is focused on two initiatives in 2026: expanding how it brings NeuroStar TMS systems to market by piloting new customer acquisition models, and driving growth in demand at Greenbrook clinics for depression treatments
60% confidenceFull-year clinic revenue grew 28% on an adjusted pro forma basis, supported by increased field engagement and a growing network of referring providers
60% confidenceNeuroStar revenue (systems plus treatment sessions) was $18.3 million, representing 9% growth year-over-year on a pro forma basis
60% confidenceCompass has completed two phase 3 studies showing highly statistically significant and clinically meaningful results, including durable improvement through at least 26 weeks after one or two doses
60% confidenceThe Spravato rollout is nearly complete, with 84 clinics providing the treatment
60% confidence